ADM
MCID: CHL028
MIFTS: 61

Childhood Type Dermatomyositis (ADM)

Categories: Bone diseases, Immune diseases, Muscle diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Childhood Type Dermatomyositis

MalaCards integrated aliases for Childhood Type Dermatomyositis:

Name: Childhood Type Dermatomyositis 11 14 33
Juvenile Dermatomyositis 11 19 58 75 16 71 31 33
Juvenile Dm 19 58
Dermatomyositis, Childhood Type 71
Dermatomyositis Sine Myositis 19
Amyopathic Dermatomyositis 19
Childhood Dermatomyositis 11
Adm 19

Characteristics:


Prevelance:

Juvenile Dermatomyositis: 1-9/1000000 (Worldwide) 58

Age Of Onset:

Juvenile Dermatomyositis: Adolescent,Childhood,Infancy 58

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare renal diseases
Rare respiratory diseases
Rare systemic and rhumatological diseases
Rare skin diseases


Summaries for Childhood Type Dermatomyositis

GARD: 19 Juvenile dermatomyositis has some similarities to adult dermatomyositis and polymyositis. Children with Juvenile dermatomyositis may have difficulty swallowing and breathing, and the heart may also be affected. About 20 to 30 percent of children with Juvenile dermatomyositis develop calcium deposits in the soft tissue. Affected children may not show higher than normal levels of the muscle enzyme creatine kinase in their blood but have higher than normal levels of other muscle enzymes.

MalaCards based summary: Childhood Type Dermatomyositis, also known as juvenile dermatomyositis, is related to interstitial lung disease and cardiovascular system disease. An important gene associated with Childhood Type Dermatomyositis is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Pirfenidone and Abatacept have been mentioned in the context of this disorder. Affiliated tissues include skin, skeletal muscle and bone, and related phenotypes are muscle weakness and fatigue

Orphanet: 58 An early-onset form of dermatomyositis (DM), a systemic, autoimmune inflammatory muscle disorder with vasculopathy, characterized by proximal and symmetrical muscle weakness, evocative skin lesions, and systemic manifestations. Vasculopathy occurs in the skin, muscle (mainly in the perifascicular area), and sometimes in the intestinal tissue.

Wikipedia: 75 Juvenile dermatomyositis (JDM) is an idiopathic inflammatory myopathy (IMM) of presumed autoimmune... more...

Related Diseases for Childhood Type Dermatomyositis

Diseases related to Childhood Type Dermatomyositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 849)
# Related Disease Score Top Affiliating Genes
1 interstitial lung disease 31.9 TNF IFIH1 ICOSLG CCR6
2 cardiovascular system disease 31.5 TNF MIR10A ICOSLG HMGCR CCR6
3 respiratory failure 31.0 TNF IFNA1 CD4 CCR6
4 nonspecific interstitial pneumonia 30.9 TRIM21 IFIH1 EXOSC10 CD4 CCR6
5 calcinosis 30.9 TNF HLA-DRB1 HLA-DQA1
6 lupus erythematosus 30.7 TRIM21 SNRNP70 MX1 IFIH1 CCR6
7 exanthem 30.6 TRIM33 TRIM21 TNF MORC3 IFNA1 IFIH1
8 telangiectasis 30.6 TRIM21 TNF SNRNP70 EXOSC10 CCR6
9 myocarditis 30.5 TNF IFNA1 IFIH1 CD4
10 cutaneous lupus erythematosus 30.5 TRIM21 MX1 IFNA1 IFIH1 ICOSLG CCR6
11 myositis 30.4 TRIM33 TRIM21 TNF SAE1 NT5C1A IFNA1
12 collagen disease 30.3 TRIM21 SNRNP70 EXOSC10 CCR6
13 human cytomegalovirus infection 30.3 TNF CD4 CCR6
14 pneumocystosis 30.3 TNF CD4 CCR6
15 autoimmune vasculitis 30.3 TNF CD4 CCR6
16 cellulitis 30.3 TNF CD4 CCR6
17 cholangitis 30.3 TNF HLA-DRB1 HLA-DQA1
18 neuromyelitis optica 30.3 IFNA1 HLA-DRB1 HLA-DQA1
19 nocardiosis 30.2 TNF CD4
20 lymphoma, mucosa-associated lymphoid type 30.2 ICOSLG CXCR5 CD4 CCR6
21 crescentic glomerulonephritis 30.2 TNF ICOSLG CD4 CCR6
22 macs syndrome 30.2 TNF IFNA1 CD4
23 sclerosing cholangitis 30.2 TNF ICOSLG CD4 CCR6
24 leukemia, chronic myeloid 30.2 MIR10A IFNA1 ICOSLG CD4 CCR6
25 lymphatic system disease 30.2 MIR10A ICOSLG CD4 CCR6
26 aphthous stomatitis 30.2 TRIM21 TNF CD4 CCR6
27 dyskinesia of esophagus 30.2 TRIM21 SNRNP70 EXOSC10
28 myopathy 30.2 TRIM33 TRIM21 TNF SNRNP70 MORC3 MIR10A
29 autoimmune gastritis 30.2 ICOSLG CD4 CCR6
30 severe acute respiratory syndrome 30.1 TNF MX1 IFNA1 IFIH1
31 t cell deficiency 30.1 ICOSLG CD4 CCR6
32 pernicious anemia 30.1 ICOSLG CD4 CCR6
33 thyroiditis 30.1 TNF IFNA1 HLA-DRB1 HLA-DQA1
34 hemophagocytic lymphohistiocytosis 30.1 TNF CD4 CCR6
35 thrombocytopenia due to platelet alloimmunization 30.1 ICOSLG CD4 CCR6
36 autoimmune peripheral neuropathy 30.1 ICOSLG CD4
37 localized scleroderma 30.1 TNF SNRNP70 EXOSC10 CD4
38 leukemia, acute myeloid 30.1 TNF MIR10A IFNA1 ICOSLG CD4 CCR6
39 lyme disease 30.1 TNF IFNA1 HLA-DRB1
40 type 1 diabetes mellitus 30.1 TNF ICOSLG HLA-DRB1 HLA-DQA1 CCR6
41 muscular disease 30.1 TRIM33 TNF MORC3 MIR10A IFIH1 ICOSLG
42 hyper ige syndrome 30.1 ICOSLG CD4 CCR6
43 mixed connective tissue disease 30.0 TNF SNRNP70 HLA-DRB1 HLA-DQA1
44 severe cutaneous adverse reaction 30.0 TNF HLA-DRB1 CD4 CCR6
45 autoimmune disease 30.0 TRIM21 TNF IFNA1 ICOSLG HLA-DRB1 HLA-DQA1
46 urinary tract infection 30.0 TNF CD4 CCR6
47 herpes zoster 30.0 IFNA1 HLA-DRB1 CD4 CCR6
48 intestinal perforation 30.0 TNF CD4 CCR6
49 deficiency anemia 30.0 TNF IFNA1 ICOSLG CD4 CCR6
50 connective tissue disease 30.0 TRIM21 TNF SNRNP70 MIR10A IFNA1 ICOSLG

Graphical network of the top 20 diseases related to Childhood Type Dermatomyositis:



Diseases related to Childhood Type Dermatomyositis

Symptoms & Phenotypes for Childhood Type Dermatomyositis

Human phenotypes related to Childhood Type Dermatomyositis:

58 30 (show all 46)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 muscle weakness 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001324
2 fatigue 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0012378
3 dry skin 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000958
4 autoimmunity 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002960
5 elevated circulating creatine kinase concentration 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0003236
6 palpebral edema 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0100540
7 myalgia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0003326
8 mucosal telangiectasiae 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0100579
9 telangiectasia of the skin 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0100585
10 erythema 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0010783
11 skin rash 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000988
12 myositis 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0100614
13 elevated erythrocyte sedimentation rate 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0003565
14 calcinosis 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0003761
15 elevated circulating c-reactive protein concentration 30 Hallmark (90%) HP:0011227
16 constipation 58 30 Frequent (33%) Frequent (79-30%)
HP:0002019
17 hypotonia 58 30 Frequent (33%) Frequent (79-30%)
HP:0001252
18 arthritis 58 30 Frequent (33%) Frequent (79-30%)
HP:0001369
19 fever 58 30 Frequent (33%) Frequent (79-30%)
HP:0001945
20 alopecia 58 30 Frequent (33%) Frequent (79-30%)
HP:0001596
21 skin ulcer 58 30 Frequent (33%) Frequent (79-30%)
HP:0200042
22 arthralgia 58 30 Frequent (33%) Frequent (79-30%)
HP:0002829
23 vasculitis 58 30 Frequent (33%) Frequent (79-30%)
HP:0002633
24 cutaneous photosensitivity 58 30 Frequent (33%) Frequent (79-30%)
HP:0000992
25 pruritus 58 30 Frequent (33%) Frequent (79-30%)
HP:0000989
26 restrictive ventilatory defect 58 30 Frequent (33%) Frequent (79-30%)
HP:0002091
27 poikiloderma 58 30 Frequent (33%) Frequent (79-30%)
HP:0001029
28 muscle spasm 58 30 Frequent (33%) Frequent (79-30%)
HP:0003394
29 dysarthria 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001260
30 dysphonia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001618
31 dysphagia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002015
32 emg abnormality 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003457
33 angina pectoris 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001681
34 abdominal pain 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002027
35 dyspnea 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002094
36 arrhythmia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0011675
37 bundle branch block 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0011710
38 cough 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012735
39 gastrointestinal hemorrhage 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002239
40 hoarse voice 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001609
41 pericarditis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001701
42 weight loss 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001824
43 limitation of joint mobility 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001376
44 cardiomyopathy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001638
45 pulmonary fibrosis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002206
46 elevated c-reactive protein level 58 Very frequent (99-80%)

MGI Mouse Phenotypes related to Childhood Type Dermatomyositis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.4 CCR6 CD4 CXCR5 HLA-DQA1 ICOSLG IFIH1

Drugs & Therapeutics for Childhood Type Dermatomyositis

Drugs for Childhood Type Dermatomyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pirfenidone Approved, Investigational Phase 4 53179-13-8 40632
2
Abatacept Approved Phase 4 332348-12-6
3 Antirheumatic Agents Phase 4
4 Anti-Inflammatory Agents Phase 4
5 Vaccines Phase 4
6 Analgesics Phase 4
7 Anti-Inflammatory Agents, Non-Steroidal Phase 4
8 Analgesics, Non-Narcotic Phase 4
9 Immune Checkpoint Inhibitors Phase 4
10 Hormones Phase 4
11 Hormone Antagonists Phase 4
12 Melanocyte-Stimulating Hormones Phase 4
13 Adrenocorticotropic Hormone Phase 4
14
beta-Endorphin Phase 4
15
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
16
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
17
Prednisolone Approved, Vet_approved Phase 3 50-24-8 4894 5755
18
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5 1875
19
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 4159 6741
20
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
21
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7 4897
22
Methylprednisolone Acetate Phase 3 584547
23 Cyclosporins Phase 3
24
Basiliximab Approved, Investigational Phase 2 179045-86-4
25
Tacrolimus Approved, Investigational Phase 2 104987-11-3 6473866 445643
26
Rituximab Approved Phase 2 174722-31-7
27
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
28
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 4112 126941
29
Mycophenolic acid Approved, Investigational Phase 2 24280-93-1 446541
30
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
31 Calcineurin Inhibitors Phase 2
32 Antineoplastic Agents, Hormonal Phase 2
33 Neuroprotective Agents Phase 2
34 Antiemetics Phase 2
35 glucocorticoids Phase 2
36 Gastrointestinal Agents Phase 2
37 Protective Agents Phase 2
38 Antidotes Phase 2
39
Sodium thiosulfate Phase 2
40 Pharmaceutical Solutions Phase 2
41 Antioxidants Phase 2
42 Chelating Agents Phase 2
43 Antineoplastic Agents, Immunological Phase 2
44 Immunosuppressive Agents Phase 2
45 Immunologic Factors Phase 2
46 Folate Phase 2
47 Vitamin B9 Phase 2
48 Anti-Bacterial Agents Phase 2
49 Anti-Infective Agents Phase 2
50 Antitubercular Agents Phase 2

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 Randomized Controlled Trial of Pirfenidone in Patients With Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
3 Abatacept for the Treatment of Refractory Juvenile Dermatomyositis Completed NCT02594735 Phase 4 Abatacept
4 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Completed NCT02245841 Phase 4 H.P. Acthar Gel
5 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
6 Five-year Single-blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine a Versus Prednisone Plus Methotrexate Completed NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
7 Basiliximab as a Treatment of Interstitial Pneumonia in Clinical Amyopathic Dermatomyositis Patients Unknown status NCT03192657 Phase 2 Basiliximab;Calcineurin Inhibitors;Steroids
8 Phase II Study of Prednisolone/Methylprednisolone Absorption in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2 Methylprednisolone;Prednisolone
9 Novel Drug Delivery of Sodium Thiosulfate for Calcinosis Associated With Adult and Juvenile Dermatomyositis Completed NCT01572844 Phase 2 Sodium thiosulfate
10 Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM) Completed NCT00106184 Phase 2 Rituximab;Placebo
11 Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis Recruiting NCT05524311 Phase 2 Baricitinib
12 Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccine (ACV01) Recruiting NCT05000216 Phase 2 Continue IS (MMF or MPA);Continue IS (MTX);Withhold IS (MMF or MPA);Withhold IS (MTX);Withhold IS (B cell depletion therapy)
13 Efficacy and Safety of Creatine Supplementation in Patients With Juvenile Systemic Lupus Erythematosus and Juvenile Dermatomyositis Unknown status NCT01217320
14 Incidence and Prevalence of Juvenile Dermatomyositis in Alsace Between 2000 to 2015 Unknown status NCT03432455
15 Retrospective Descriptive Study of Juvenile Dermatomyositis in Alsace Unknown status NCT03433638
16 Clinical Analysis of 12 Cases of Juvenile Dermatomyositis Treated With Methylprednisolone Repeated Intermittent Pulse Combined With Mycophenolate Mofetil Completed NCT05509140
17 The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis Completed NCT02267005
18 The CARRA Registry Completed NCT01697254
19 Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area Completed NCT03430388
20 Studies of Natural History, Pathogenesis, and Outcomes in Autoimmune and Inflammatory Diseases Including Juvenile Dermatomyositis Recruiting NCT00059748
21 Environmental Risk Factors for the Anti-Synthetase Syndrome Recruiting NCT01276470
22 Correlation Between the Change of Peripheral Lymphocyte Subsets and Clinically Amyopathic Dermatomyositis Combined With Rapidly Progressive Interstitial Lung Disease Recruiting NCT04613219 Tofacitinib 5 MG [Xeljanz]
23 TRACER: Transition to Adulthood Through Coaching and Empowerment in Rheumatology, A Feasibility Study Not yet recruiting NCT05545839
24 Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI and Severe Juvenile Dermatomyositis No longer available NCT01724580 Baricitinib

Search NIH Clinical Center for Childhood Type Dermatomyositis

Genetic Tests for Childhood Type Dermatomyositis

Anatomical Context for Childhood Type Dermatomyositis

Organs/tissues related to Childhood Type Dermatomyositis:

MalaCards : Skin, Skeletal Muscle, Bone, Heart, Lung, T Cells, Endothelial

Publications for Childhood Type Dermatomyositis

Articles related to Childhood Type Dermatomyositis:

(show top 50) (show all 1978)
# Title Authors PMID Year
1
The clinical features of juvenile dermatomyositis: A single-centre inception cohort. 62
36183479 2022
2
Cardiac involvement in anti-MDA5 dermatomyositis: a case-based review. 62
36454342 2022
3
Mechanic Hands/Hiker Feet in a Patient With Amyopathic Dermatomyositis and Interstitial Lung Disease. 62
36395446 2022
4
[[Translated article]]Juvenile Dermatomyositis During the SARS-CoV-2 Pandemic: Acral and Oral Mucosal Involvement. 62
36464006 2022
5
Use of Adalimumab in a Child with Juvenile Dermatomyositis and Calcinosis. 62
36324016 2022
6
[Chinese guidelines for the diagnosis and treatment of juvenile dermatomyositis]. 62
36444423 2022
7
Palmar erythema: A diagnostic clue of juvenile dermatomyositis. 62
36468501 2022
8
Assessment of Thigh MRI Radiomics and Clinical Characteristics for Assisting in Discrimination of Juvenile Dermatomyositis. 62
36431189 2022
9
Bisphosphonate therapy for juvenile dermatomyositis-associated calcinosis and metaphyseal zebra lines. 62
36343985 2022
10
Early-onset juvenile dermatomyositis: A tertiary referral center experience and review of the literature. 62
36434896 2022
11
Two Distinct Immune Cell Signatures Predict the Clinical Outcomes in Patients With Amyopathic Dermatomyositis With Interstitial Lung Disease. 62
35713981 2022
12
Anti-MDA5 antibody-associated clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease. 62
36108903 2022
13
A case of clinically amyopathic dermatomyositis in a Filipino woman. 62
36184686 2022
14
Melanoma differentiation-associated gene 5 amyopathic dermatomyositis following an acute Mycoplasma pneumoniae infection: a case report. 62
36316755 2022
15
Obesity as a comorbidity in children and adolescents with autoimmune rheumatic diseases. 62
36394598 2022
16
Early Abnormal Nailfold Capillary Changes Are Predictive of Calcinosis Development in Juvenile Dermatomyositis. 62
35914785 2022
17
Linear morphea with overlying lichen sclerosus and calcinosis cutis associated with juvenile dermatomyositis. 62
36384242 2022
18
Therapeutic plasma exchange for steroid refractory idiopathic inflammatory myopathies with interstitial lung disease. 62
36408807 2022
19
Hepatic veno-occlusive disease accompanied by thrombotic microangiopathy developing during treatment of juvenile dermatomyositis and macrophage activation syndrome: A case report. 62
36416547 2022
20
Efficacy and tolerance of corticosteroids and methotrexate in patients with juvenile dermatomyositis: a retrospective cohort study. 62
35199139 2022
21
Juvenile Dermatomyositis: what comes next? Long-term outcomes in childhood myositis from a patient perspective. 62
36384526 2022
22
Anti-Valosin-Containing Protein (VCP/p97) Autoantibodies in Inclusion Body Myositis and Other Inflammatory Myopathies. 62
36373433 2022
23
Calcified dyspigmented plaques, discharging sinuses and guttate hypopigmentation: An unusual clinical presentation of clinically amyopathic dermatomyositis. 62
36332085 2022
24
Juvenile dermatomyositis associated with autoantibodies to small ubiquitin-like modifier activating enzyme: a report of 4 cases from North India and a review of literature. 62
36278969 2022
25
Challenges in diagnosing COVID-19 related disease in pediatric patients with rheumatic disease. 62
34850910 2022
26
Chemotherapy induced juvenile dermatomyositis: a novel presentation- a case report. 62
36316673 2022
27
Assessment of the outcomes of SARS-CoV-2 infection in children and young people followed at Portuguese pediatric rheumatology clinics. 62
36056926 2022
28
Masseter idiopathic calcinosis circumscripta: A rare condition. 62
35235881 2022
29
Juvenile dermatomyositis-associated calcinosis successfully treated with combined immunosuppressive, bisphosphonate, oral baricitinib and physical therapy. 62
36286617 2022
30
Spontaneous pneumomediastinum, a rare manifestation of clinically amyopathic dermatomyositis. 62
36057086 2022
31
Whole-body MR imaging in evaluation of children with juvenile dermatomyositis. 62
35998441 2022
32
Clinically amyopathic dermatomyositis with diffuse erosive erythema in a patient with anti-small ubiquitin-like modifier activating enzyme antibody. 62
35106751 2022
33
Comment on: Association of anti-HSC70 autoantibodies with cutaneous ulceration and severe disease in juvenile dermatomyositis. 62
36218414 2022
34
Clinical features and immune-related protein patterns of anti-MDA5 positive clinically amyopathic dermatomyositis Dutch patients. 62
35048953 2022
35
Does the BNT162b2 Vaccine Trigger Antimelanoma Differentiation-Associated Gene 5 Antibody-Positive Interstitial Lung Disease? 62
36182114 2022
36
COVID-19 quarantine in adolescents with autoimmune rheumatic diseases: mental health issues and life conditions. 62
35701628 2022
37
Onset of amyopathic dermatomyositis following mRNA-based SARS-CoV-2 vaccination. 62
35536636 2022
38
Satisfactory Response to Pulsed Dye Laser Treatment of Facial Erythema in a Patient with Amyopathic Dermatomyositis. 62
36115383 2022
39
Correction: Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review. 62
36064710 2022
40
Preclinical ocular microvascular changes in juvenile dermatomyositis: A pilot optical coherence tomography angiography study. 62
35605694 2022
41
Juvenile Dermatomyositis With Macrophage Activation and Severe Encephalopathy. 62
36101954 2022
42
Adult and juvenile dermatomyositis treatment. 62
36065712 2022
43
Calcinosis cutis with amyopathic dermatomyositis. 62
35731215 2022
44
A case of juvenile amyopathic dermatomyositis with anti-transcription intermediary factor 1-α antibody showing negative anti-TIF1-γ ELISA results: Comment on "Case of pembrolizumab-induced dermatomyositis with anti-transcription intermediary factor 1-γ antibody". 62
36176040 2022
45
Epidemiology conduction of paediatric rheumatic diseases based on the registry database of the Pediatric Rheumatology Association of Japan. 62
36112493 2022
46
[Lack of therapeutic response: Is it really a rheumatoid Arthritis?] 62
36030790 2022
47
Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese community hospital. 62
35399148 2022
48
Performance of the 2017 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria in Patients With Idiopathic Inflammatory Myopathy and Anti-Melanoma Differentiation-Associated Protein 5 Positivity. 62
35467787 2022
49
A Systematic Review and Metaanalysis of Predictors of Mortality in Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease. 62
36379584 2022
50
Genetic analysis for type 1 diabetes genes in juvenile dermatomyositis unveils genetic disease overlap. 62
35171267 2022

Variations for Childhood Type Dermatomyositis

Expression for Childhood Type Dermatomyositis

LifeMap Discovery
Genes differentially expressed in tissues of Childhood Type Dermatomyositis patients vs. healthy controls: 35 (show all 35)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFIT3 interferon induced protein with tetratricopeptide repeats 3 Skeletal Muscle + 5.58 0.000
2 ISG15 ISG15 ubiquitin like modifier Skeletal Muscle + 5.25 0.000
3 XIST X inactive specific transcript Skeletal Muscle + 5.14 0.000
4 RSAD2 radical S-adenosyl methionine domain containing 2 Skeletal Muscle + 4.94 0.000
5 GBP1 guanylate binding protein 1 Skeletal Muscle + 4.88 0.000
6 CMPK2 cytidine/uridine monophosphate kinase 2 Skeletal Muscle + 4.61 0.000
7 IFI44L interferon induced protein 44 like Skeletal Muscle + 4.42 0.000
8 MX1 MX dynamin like GTPase 1 Skeletal Muscle + 4.40 0.000
9 IFI44 interferon induced protein 44 Skeletal Muscle + 4.34 0.000
10 IFIT2 interferon induced protein with tetratricopeptide repeats 2 Skeletal Muscle + 3.96 0.000
11 IFI27 interferon alpha inducible protein 27 Skeletal Muscle + 3.86 0.000
12 CXCL11 C-X-C motif chemokine ligand 11 Skeletal Muscle + 3.67 0.000
13 RPS4Y1 ribosomal protein S4 Y-linked 1 Skeletal Muscle - 3.57 0.000
14 IFIT1 interferon induced protein with tetratricopeptide repeats 1 Skeletal Muscle + 3.57 0.000
15 MYH3 myosin heavy chain 3 Skeletal Muscle + 3.54 0.000
16 SAMHD1 SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1 Skeletal Muscle + 3.52 0.000
17 XAF1 XIAP associated factor 1 Skeletal Muscle + 3.44 0.000
18 KLHDC7B kelch domain containing 7B Skeletal Muscle + 3.44 0.000
19 IFI6 interferon alpha inducible protein 6 Skeletal Muscle + 3.43 0.000
20 IFIH1 interferon induced with helicase C domain 1 Skeletal Muscle + 3.43 0.000
21 PARP12 poly(ADP-ribose) polymerase family member 12 Skeletal Muscle + 3.41 0.000
22 IFI16 interferon gamma inducible protein 16 Skeletal Muscle + 3.40 0.000
23 PLSCR1 phospholipid scramblase 1 Skeletal Muscle + 3.37 0.000
24 STAT1 signal transducer and activator of transcription 1 Skeletal Muscle + 3.37 0.000
25 PSMB8 proteasome 20S subunit beta 8 Skeletal Muscle + 3.35 0.000
26 NNMT nicotinamide N-methyltransferase Skeletal Muscle + 3.31 0.000
27 TRIM22 tripartite motif containing 22 Skeletal Muscle + 3.27 0.000
28 DTX3L deltex E3 ubiquitin ligase 3L Skeletal Muscle + 3.23 0.000
29 EIF2AK2 eukaryotic translation initiation factor 2 alpha kinase 2 Skeletal Muscle + 3.14 0.000
30 IRF7 interferon regulatory factor 7 Skeletal Muscle + 3.13 0.000
31 OAS1 2'-5'-oligoadenylate synthetase 1 Skeletal Muscle + 3.09 0.000
32 IFITM1 interferon induced transmembrane protein 1 Skeletal Muscle + 3.06 0.000
33 TNFSF10 TNF superfamily member 10 Skeletal Muscle + 3.05 0.000
34 PARP9 poly(ADP-ribose) polymerase family member 9 Skeletal Muscle + 3.05 0.000
35 POSTN periostin Skeletal Muscle + 3.03 0.000
Search GEO for disease gene expression data for Childhood Type Dermatomyositis.

Pathways for Childhood Type Dermatomyositis

GO Terms for Childhood Type Dermatomyositis

Cellular components related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.4 TNF ICOSLG HLA-DRB1 CXCR5 CD4 CCR6

Biological processes related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 10.14 TNF HLA-DRB1 HLA-DQA1 CXCR5 CD4 CCR6
2 negative regulation of viral genome replication GO:0045071 9.91 TNF MX1 IFIH1
3 calcium-mediated signaling GO:0019722 9.86 CCR6 CD4 CXCR5 TNF
4 defense response GO:0006952 9.85 TNF MX1 IFNA1 ICOSLG
5 positive regulation of T cell activation GO:0050870 9.8 HLA-DRB1 HLA-DQA1 CD4
6 immune system process GO:0002376 9.7 MX1 MORC3 IFIH1 ICOSLG HLA-DRB1 HLA-DQA1
7 humoral immune response GO:0006959 9.56 TNF IFNA1 HLA-DRB1 CCR6
8 positive regulation of viral entry into host cell GO:0046598 9.1 TRIM21 HLA-DRB1 CD4

Molecular functions related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II protein complex binding GO:0023026 9.1 HLA-DRB1 HLA-DQA1 CD4

Sources for Childhood Type Dermatomyositis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....